{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T16:40:08Z","timestamp":1746895208045,"version":"3.40.5"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005790","name":"Thammasat University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005790","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thailand Science Research and Innovation Fundamental Fund Fiscal Year 2023"},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A671041."],"award-info":[{"award-number":["N42A671041."]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91968-z","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T03:54:34Z","timestamp":1746849274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A molecular network analysis and in silico docking of beta-eudesmol, atractylodin and hinesol in patients with advance stage intrahepatic cholangiocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Teerachat","family":"Saeheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Vindvamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanna","family":"Chaijaorenkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisit","family":"Tongsiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kesara","family":"Na-Bangchang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"91968_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17:9","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17:9, 557\u2013588. https:\/\/doi.org\/10.1038\/s41575-020-0310-z (2020). Epub 2020 Jun 30.","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"91968_CR2","doi-asserted-by":"publisher","first-page":"5929234","DOI":"10.1155\/2017\/5929234","volume":"2017","author":"K Na-Bangchang","year":"2017","unstructured":"Na-Bangchang, K., Plengsuriyakarn, T. & Karbwang, J. Research and development of atractylodes lancea (Thunb) DC. as a promising candidate for cholangiocarcinoma chemotherapeutics. Evid. Based Complement. Alternat Med. 2017, 5929234. https:\/\/doi.org\/10.1155\/2017\/5929234 (2017).","journal-title":"Evid. Based Complement. Alternat Med."},{"key":"91968_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/JEP.S177032","volume":"10","author":"P Martviset","year":"2018","unstructured":"Martviset, P., Chaijaroenkul, W., Muhamad, P. & Na-Bangchang, K. Bioactive constituents isolated from Atractylodes lancea (Thunb.) DC. rhizome exhibit synergistic effect against cholangiocarcinoma cell. J. Exp. Pharmacol. 10, 59\u201364 (2018).","journal-title":"J. Exp. Pharmacol."},{"issue":"2","key":"91968_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jphs.2017.09.033","volume":"136","author":"K Kotawong","year":"2018","unstructured":"Kotawong, K., Chaijaroenkul, W., Muhamad, P. & Na-Bangchang, K. Cytotoxic activities and effects of atractylodin and \u03b2-eudesmol on the cell cycle arrest and apoptosis on cholangiocarcinoma cell line. J. Pharmacol. Sci. 136(2), 51\u201356. https:\/\/doi.org\/10.1016\/j.jphs.2017.09.033 (2018).","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"91968_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40360-018-0223-4","volume":"19","author":"P Srijiwangsa","year":"2018","unstructured":"Srijiwangsa, P., Ponnikorn, S. & Na-Bangchang, K. Effect of \u03b2-eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. BMC Pharmacol. Toxicol. 19(1), 32. https:\/\/doi.org\/10.1186\/s40360-018-0223-4 (2018).","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"8","key":"91968_CR6","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.31557\/APJCP.2022.23.8.2573","volume":"23","author":"B Acharya","year":"2022","unstructured":"Acharya, B., Chajaroenkul, W. & Na-Bangchang, K. \u03b2-Eudesmol inhibits the migration of cholangiocarcinoma cells by suppressing epithelial-mesenchymal transition via PI3K\/AKT and p38MAPK modulation. Asian Pac. J. Cancer Prev. 23 (8), 2573\u20132581. https:\/\/doi.org\/10.31557\/APJCP.2022.23.8.2573 (2022).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"91968_CR7","doi-asserted-by":"publisher","first-page":"108980","DOI":"10.1016\/j.cbpc.2021.108980","volume":"243","author":"G Tshering","year":"2021","unstructured":"Tshering, G., Pimtong, W., Plengsuriyakarn, T. & Na-Bangchang, K. Anti-angiogenic effects of beta-eudesmol and atractylodin in developing zebrafish embryos. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 243, 108980. https:\/\/doi.org\/10.1016\/j.cbpc.2021.108980 (2021).","journal-title":"Comp. Biochem. Physiol. C Toxicol. Pharmacol."},{"issue":"9","key":"91968_CR8","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.31557\/APJCP.2022.23.9.3093","volume":"23","author":"P Sonsomnuek","year":"2022","unstructured":"Sonsomnuek, P., Tarasuk, M., Plengsuriyakarn, T., Boonprasert, K. & Na-Bangchang, K. Apoptotic and anti-metastatic effects of Atractylodes lancea (Thunb.) DC. in a Hamster model of cholangiocarcinoma. Asian Pac. J. Cancer Prev. 23 (9), 3093\u20133101. https:\/\/doi.org\/10.31557\/APJCP.2022.23.9.3093 (2022).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"91968_CR9","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3389\/fphar.2018.01472","volume":"9","author":"J Zuo","year":"2018","unstructured":"Zuo, J. et al. Integrating molecular network and metabolomics study on anti-rheumatic mechanisms and antagonistic effects against methotrexate-induced toxicity of Qing-Luo-Yin. Front. Pharmacol. 9, 1472. https:\/\/doi.org\/10.3389\/fphar.2018.01472 (2018). [old: 5].","journal-title":"Front. Pharmacol."},{"issue":"1","key":"91968_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12906-021-03425-9","volume":"21","author":"Z Liu","year":"2021","unstructured":"Liu, Z., Ma, H. & Lai, Z. Revealing the potential mechanism of Astragalus membranaceus improving prognosis of hepatocellular carcinoma by combining transcriptomics and molecular network. BMC Complement. Med. Ther. 21(1), 263. https:\/\/doi.org\/10.1186\/s12906-021-03425-9 (2021).","journal-title":"BMC Complement. Med. Ther."},{"key":"91968_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1186\/s12906-023-04254-8","volume":"23","author":"Y Lu","year":"2023","unstructured":"Lu, Y., Dong, K., Yang, M. & Liu, J. Molecular network-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer. BMC Complement. Med. Ther. 23, 1433. https:\/\/doi.org\/10.1186\/s12906-023-04254-8 (2023).","journal-title":"BMC Complement. Med. Ther."},{"key":"91968_CR12","unstructured":"Na-Bangchang, K. et al. Phase IIa clinical trial to evaluate safety and efficacy of capsule formulation of the standardized extract of Atractylodes lancea (Thunb) DC in patients with advanced-stage intrahepatic cholangiocarcinoma. J. Tradit Complement. Med. (2023). (In press)."},{"issue":"1","key":"91968_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12906-021-03340-z","volume":"21","author":"R Odongo","year":"2021","unstructured":"Odongo, R., Demiroglu-Zergeroglu, A. & \u00c7ak\u0131r, T. A systems pharmacology approach based on oncogenic signalling pathways to determine the mechanisms of action of natural products in breast cancer from transcriptome data. BMC Complement. Med. Ther. 21(1), 181. https:\/\/doi.org\/10.1186\/s12906-021-03340-z (2021).","journal-title":"BMC Complement. Med. Ther."},{"issue":"3","key":"91968_CR14","doi-asserted-by":"publisher","first-page":"e001946","DOI":"10.1136\/jitc-2020-001946","volume":"9","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J. Immunother Cancer 9(3), e001946. https:\/\/doi.org\/10.1136\/jitc-2020-001946 (2021).","journal-title":"J. Immunother Cancer"},{"issue":"6","key":"91968_CR15","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1007\/s13277-013-0945-2","volume":"34","author":"S Yothaisong","year":"2013","unstructured":"Yothaisong, S. et al. Increased activation of PI3K\/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K\/mTOR Inhibition presents a possible therapeutic strategy. Tumour Biol. 34(6), 3637\u20133648. https:\/\/doi.org\/10.1007\/s13277-013-0945-2 (2013).","journal-title":"Tumour Biol."},{"key":"91968_CR16","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1007\/s12032-014-0940-5","volume":"31","author":"Z Fang","year":"2014","unstructured":"Fang, Z., Lu, L., Tian, Z. & Luo, K. Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma. Med. Oncol. 31, 5940. https:\/\/doi.org\/10.1007\/s12032-014-0940-5 (2014).","journal-title":"Med. Oncol."},{"issue":"1","key":"91968_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38(1), 13\u201325. https:\/\/doi.org\/10.1016\/j.immuni.2013.01.004 (2013).","journal-title":"Immunity"},{"issue":"9","key":"91968_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/jpm11090888","volume":"11","author":"P Biswas","year":"2021","unstructured":"Biswas, P. et al. Analysis of SYK gene as a prognostic biomarker and suggested potential bioactive phytochemicals as an alternative therapeutic option for colorectal cancer: an in-silico pharmaco-Informatics investigation. J. Pers. Med. 11 (9), 888. https:\/\/doi.org\/10.3390\/jpm11090888 (2021).","journal-title":"J. Pers. Med."},{"key":"91968_CR19","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3892\/ol.2017.7570","volume":"15","author":"Q Kang","year":"2018","unstructured":"Kang, Q. et al. Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma. Oncol. Lett. 15, 2161\u20132168. https:\/\/doi.org\/10.3892\/ol.2017.7570 (2018).","journal-title":"Oncol. Lett."},{"key":"91968_CR20","doi-asserted-by":"crossref","unstructured":"Chen, L. & Tiannqianng, S. Multi-omics characterization of cholangiocarcinoma and association with prognostic and therapeutic molecular subtypes (abstract). ASCO Supplemennt_1.60 (2023)","DOI":"10.1200\/GO.2023.9.Supplement_1.60"},{"issue":"1","key":"91968_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-022-01253-z","volume":"15","author":"T Xia","year":"2022","unstructured":"Xia, T. et al. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. J. Hematol. Oncol. 15(1), 37. https:\/\/doi.org\/10.1186\/s13045-022-01253-z (2022).","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"91968_CR22","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1158\/0008-5472.CAN-03-2770","volume":"64","author":"M Taniai","year":"2004","unstructured":"Taniai, M. et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64(10), 3517\u20133524. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-2770 (2004).","journal-title":"Cancer Res."},{"issue":"7","key":"91968_CR23","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1053\/j.gastro.2005.03.010","volume":"128","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi, S., Werneburg, N. W., Bronk, S. F., Kaufmann, S. H. & Gores, G. J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128(7), 2054\u20132065. https:\/\/doi.org\/10.1053\/j.gastro.2005.03.010 (2005).","journal-title":"Gastroenterology"},{"key":"91968_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fmed.2019.00293","volume":"6","author":"S Roy","year":"2019","unstructured":"Roy, S., Glaser, S. & Chakraborty, S. Inflammation and progression of cholangiocarcinoma: Role of angiogenic and lymphangiogenic mechanisms. Front. Med. (Lausanne) 6, 293. https:\/\/doi.org\/10.3389\/fmed.2019.00293 (2019).","journal-title":"Front. Med. (Lausanne)"},{"key":"91968_CR25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","volume":"75","author":"L Ma","year":"2021","unstructured":"Ma, L. et al. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Hepatol. 75, 1397\u20131408. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.028 (2021).","journal-title":"J. Hepatol."},{"key":"91968_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/cdd.2011.158","volume":"19","author":"M Vogler","year":"2012","unstructured":"Vogler, M. BCL2A1: The underdog in the BCL2 family. Cell. Death Differ. 19, 67\u201374. https:\/\/doi.org\/10.1038\/cdd.2011.158 (2012).","journal-title":"Cell. Death Differ."},{"key":"91968_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/tx9003193","volume":"23","author":"J Pan","year":"2010","unstructured":"Pan, J. et al. Reactive oxygen species-activated akt\/ask1\/p38 signaling pathway in nickel compound-induced apoptosis in Beas 2b cells. Chem. Res. Toxicol. 23, 568\u2013557 (2010).","journal-title":"Chem. Res. Toxicol."},{"issue":"9","key":"91968_CR28","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1074\/jbc.273.9.5067","volume":"273","author":"NJ Donato","year":"1998","unstructured":"Donato, N. J. & Perez, M. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. J. Biol. Chem. 273(9), 5067\u20135072. https:\/\/doi.org\/10.1074\/jbc.273.9.5067 (1998).","journal-title":"J. Biol. Chem."},{"key":"91968_CR29","doi-asserted-by":"publisher","first-page":"742049","DOI":"10.3389\/fcell.2021.742049","volume":"9","author":"A G\u00e1mez-Garc\u00eda","year":"2021","unstructured":"G\u00e1mez-Garc\u00eda, A. et al. ERK5 Inhibition induces autophagy-mediated cancer cell death by activating ER stress. Front. Cell. Dev. Biol. 9, 742049. https:\/\/doi.org\/10.3389\/fcell.2021.742049 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"26","key":"91968_CR30","doi-asserted-by":"publisher","first-page":"10690","DOI":"10.1073\/pnas.0812254106","volume":"106","author":"T Stoyanova","year":"2009","unstructured":"Stoyanova, T., Roy, N., Kopanja, D., Bagchi, S. & Raychaudhuri, P. DDB2 decides cell fate following DNA damage. Proc. Natl. Acad. Sci. U S A. 106(26), 10690\u201310695. https:\/\/doi.org\/10.1073\/pnas.0812254106 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"6","key":"91968_CR31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","volume":"105","author":"I Prager","year":"2019","unstructured":"Prager, I. & Watzl, C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J. Leukoc. Biol. 105(6), 1319\u20131329. https:\/\/doi.org\/10.1002\/JLB.MR0718-269R (2019).","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"91968_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1365-3083.1983.tb00865.x","volume":"18","author":"TD Moon","year":"1983","unstructured":"Moon, T. D., Morley, J. E., Vessella, R. L. & Lange, P. H. The role of calmodulin in human natural killer cell activity. Scand. J. Immunol. 18(3), 255\u2013258. https:\/\/doi.org\/10.1111\/j.1365-3083.1983.tb00865.x (1983).","journal-title":"Scand. J. Immunol."},{"issue":"3","key":"91968_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00432-021-03842","volume":"148","author":"Y Yan","year":"2022","unstructured":"Yan, Y., Gao, Z., Han, H., Zhao, Y. & Zhang, Y. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma. J. Cancer Res. Clin. Oncol. 148(3), 565\u2013575. https:\/\/doi.org\/10.1007\/s00432-021-03842- (2022).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"91968_CR34","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/eji.201344046","volume":"44","author":"M Poltorak","year":"2014","unstructured":"Poltorak, M., Meinert, I., Stone, J. C., Schraven, B. & Simeoni, L. Sos1 regulates sustained TCR-mediated Erk activation. Eur. J. Immunol. 44(5), 1535\u20131540. https:\/\/doi.org\/10.1002\/eji.201344046 (2014).","journal-title":"Eur. J. Immunol."},{"key":"91968_CR35","doi-asserted-by":"publisher","first-page":"37274","DOI":"10.18632\/oncotarget.26403","volume":"9","author":"J Vaquero","year":"2018","unstructured":"Vaquero, J., Lobe, C. & Fouassier, L. Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma. Oncotarget 9, 37274\u201337275. https:\/\/doi.org\/10.18632\/oncotarget.26403 (2018).","journal-title":"Oncotarget"},{"issue":"1","key":"91968_CR36","doi-asserted-by":"publisher","first-page":"e0191593","DOI":"10.1371\/journal.pone.0191593","volume":"13","author":"C Peraldo-Neia","year":"2018","unstructured":"Peraldo-Neia, C. et al. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. PLoS One 13(1), e0191593. https:\/\/doi.org\/10.1371\/journal.pone.0191593 (2018).","journal-title":"PLoS One"},{"key":"91968_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bbrc.2010.11.130","volume":"405","author":"H Yoon","year":"2011","unstructured":"Yoon, H., Min, J. K., Lee, J. W., Kim, D. G. & Hong, H. J. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1\/2. Biochem. Biophys. Res. Commun. 405, 3. https:\/\/doi.org\/10.1016\/j.bbrc.2010.11.130 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"32","key":"91968_CR38","doi-asserted-by":"publisher","first-page":"11721","DOI":"10.1073\/pnas.1412390111","volume":"111","author":"S De","year":"2014","unstructured":"De, S., Dermawan, J. K. & Stark, G. R. EGF receptor uses SOS1 to drive constitutive activation of NF\u03baB in cancer cells. Proc. Natl. Acad. Sci. U S A. 111(32), 11721\u201311726. https:\/\/doi.org\/10.1073\/pnas.1412390111 (2014).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"6","key":"91968_CR39","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s13277-012-0491-3","volume":"33","author":"W Loilome","year":"2012","unstructured":"Loilome, W. et al. PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group. Tumour Biol. 33(6), 2289\u20132298. https:\/\/doi.org\/10.1007\/s13277-012-0491-3 (2012).","journal-title":"Tumour Biol."},{"issue":"6","key":"91968_CR40","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.21037\/jgo-21-776","volume":"12","author":"Y Zheng","year":"2021","unstructured":"Zheng, Y. et al. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma. J. Gastrointest. Oncol. 12(6), 2631\u20132642. https:\/\/doi.org\/10.21037\/jgo-21-776 (2021).","journal-title":"J. Gastrointest. Oncol."},{"key":"91968_CR41","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1080\/21691401.2019.1669616","volume":"47","author":"D Ma","year":"2019","unstructured":"Ma, D., Lian, F. & Wang, X. PLCG2 promotes hepatocyte proliferation in vitro via NF-\u03baB and ERK pathway by targeting bcl2, Myc and ccnd1. Artif. Cells Nanomed. Biotechnol. 47, 1:3786\u20133792. https:\/\/doi.org\/10.1080\/21691401.2019.1669616 (2019).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"3","key":"91968_CR42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2353\/ajpath.2006.050464","volume":"169","author":"D Alvaro","year":"2006","unstructured":"Alvaro, D. et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am. J. Pathol. 169(3), 877\u2013888. https:\/\/doi.org\/10.2353\/ajpath.2006.050464 (2006).","journal-title":"Am. J. Pathol."},{"issue":"17","key":"91968_CR43","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/1078-0432.CCR-17-3725","volume":"24","author":"J Vaquero","year":"2018","unstructured":"Vaquero, J. et al. The IGF2\/IR\/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR Inhibition in cholangiocarcinoma. Clin. Cancer Res. 24(17), 4282\u20134296. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3725 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"91968_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/1947601911407323","volume":"2","author":"D Matallanas","year":"2011","unstructured":"Matallanas, D. et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2(3), 232\u2013260. https:\/\/doi.org\/10.1177\/1947601911407323 (2011).","journal-title":"Genes Cancer"},{"issue":"3","key":"91968_CR45","doi-asserted-by":"publisher","first-page":"e12694","DOI":"10.1111\/sji.12694","volume":"88","author":"NR West","year":"2018","unstructured":"West, N. R., Owens, B. M. J. & Hegazy, A. N. The oncostatin M-stromal cell axis in health and disease. Scand. J. Immunol. 88(3), e12694. https:\/\/doi.org\/10.1111\/sji.12694 (2018).","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"91968_CR46","doi-asserted-by":"publisher","first-page":"20220755","DOI":"10.1515\/biol-2022-0755","volume":"18","author":"J Dai","year":"2023","unstructured":"Dai, J. et al. SPOP regulates the expression profiles and alternative splicing events in human hepatocytes. Open. Life Sci. 18(1), 20220755. https:\/\/doi.org\/10.1515\/biol-2022-0755 (2023).","journal-title":"Open. Life Sci."},{"issue":"5","key":"91968_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00438-023-02029-x","volume":"298","author":"A Ali","year":"2023","unstructured":"Ali, A., Nimisha, Sharma, A. K., Mishra, P. K. & Saluja, S. S. Clinical significance of SPOP and APC gene alterations in colorectal cancer in Indian population. Mol. Genet. Genomics 298(5), 1087\u20131105. https:\/\/doi.org\/10.1007\/s00438-023-02029-x (2023).","journal-title":"Mol. Genet. Genomics"},{"key":"91968_CR48","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1007\/s11605-015-2767-6","volume":"19","author":"J Xu","year":"2015","unstructured":"Xu, J. et al. Properties and clinical relevance of speckle-type POZ protein in human colorectal cancer. J. Gastrointest. Surg. 19, 1484\u20131496. https:\/\/doi.org\/10.1007\/s11605-015-2767-6 (2015).","journal-title":"J. Gastrointest. Surg."},{"key":"91968_CR49","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ijo.2016.3609","volume":"49","author":"W Zhao","year":"2016","unstructured":"Zhao, W., Zhou, J., Deng, Z., Gao, Y. & Cheng, Y. SPOP promotes tumor progression via activation of beta-catenin\/TCF4 complex in clear cell renal cell carcinoma. Int. J. Oncol. 49, 1001\u20131008. https:\/\/doi.org\/10.3892\/ijo.2016.3609 (2016).","journal-title":"Int. J. Oncol."},{"issue":"2","key":"91968_CR50","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1002\/ctm2.683","volume":"12","author":"D Wan","year":"2022","unstructured":"Wan, D. et al. PRKAR2A-derived circular RNAs promote the malignant transformation of colitis and distinguish patients with colitis-associated colorectal cancer. Clin. Transl Med. 12 (2), e683. https:\/\/doi.org\/10.1002\/ctm2.683 (2022).","journal-title":"Clin. Transl Med."},{"key":"91968_CR51","doi-asserted-by":"publisher","first-page":"706838","DOI":"10.3389\/fonc.2021.706838","volume":"11","author":"T Duan","year":"2021","unstructured":"Duan, T., Zhou, D., Yao, Y. & Shao, X. The association of aberrant expression of FGF1 and mTOR-S6K1 in colorectal Cancer. Front. Oncol. 11, 706838. https:\/\/doi.org\/10.3389\/fonc.2021.706838 (2021). Erratum in: Front Oncol. 2021;11:792453.","journal-title":"Front. Oncol."},{"key":"91968_CR52","doi-asserted-by":"publisher","unstructured":"Mehta, A. K., Gracias, D. T. & Croft, M. TNF activity and T cells. Cytokine 101, 14\u201318. https:\/\/doi.org\/10.1016\/j.cyto.2016.08.003 (2018).","DOI":"10.1016\/j.cyto.2016.08.003"},{"key":"91968_CR53","first-page":"3939","volume":"30","author":"H Uramoto","year":"2010","unstructured":"Uramoto, H., Aky\u00fcrek, L. M. & Hanagiri, T. A positive relationship between filamin and VEGF in patients with lung cancer. Anticancer Res. 30, 10:3939\u20133944 (2010).","journal-title":"Anticancer Res."},{"key":"91968_CR54","doi-asserted-by":"publisher","first-page":"2352139","DOI":"10.1155\/2018\/2352139","volume":"2018","author":"Y Huang","year":"2018","unstructured":"Huang, Y. et al. High expression of ITGA3 promotes proliferation and cell cycle progression and indicates poor prognosis in intrahepatic cholangiocarcinoma. Biomed. Res. Int. 2018, 2352139. https:\/\/doi.org\/10.1155\/2018\/2352139 (2018).","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"91968_CR55","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.gendis.2023.04.010","volume":"11","author":"P Ning","year":"2023","unstructured":"Ning, P. et al. PLAU plays a functional role in driving lung squamous cell carcinoma metastasis. Genes Dis. 11(2), 554\u2013557. https:\/\/doi.org\/10.1016\/j.gendis.2023.04.010 (2023).","journal-title":"Genes Dis."},{"issue":"1","key":"91968_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/excr.1995.1057","volume":"217","author":"SC Wen","year":"1995","unstructured":"Wen, S. C. et al. ets-2 regulates cdc2 kinase activity in mammalian cells: coordinated expression of cdc2 and Cyclin A. Exp. Cell. Res. 217(1), 8\u201314. https:\/\/doi.org\/10.1006\/excr.1995.1057 (1995).","journal-title":"Exp. Cell. Res."},{"issue":"4","key":"91968_CR57","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/0008-5472.CAN-09-1474","volume":"70","author":"T Zabuawala","year":"2010","unstructured":"Zabuawala, T. et al. An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res. 70(4), 1323\u20131333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1474 (2010).","journal-title":"Cancer Res."},{"key":"91968_CR58","doi-asserted-by":"publisher","first-page":"1011762","DOI":"10.3389\/fonc.2022.1011762","volume":"12","author":"J Szymczyk","year":"2022","unstructured":"Szymczyk, J. et al. FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT via two independent mechanisms. Front. Oncol. 12, 1011762. https:\/\/doi.org\/10.3389\/fonc.2022.1011762 (2022).","journal-title":"Front. Oncol."},{"key":"91968_CR59","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/0008-5472.CAN-13-2104","volume":"74","author":"J Hong","year":"2014","unstructured":"Hong, J. et al. Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res. 74, 6:1845\u20131856. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2104 (2014).","journal-title":"Cancer Res."},{"key":"91968_CR60","doi-asserted-by":"publisher","first-page":"61878","DOI":"10.3390\/cancers15061878","volume":"15","author":"M Oba","year":"2023","unstructured":"Oba, M. et al. CCR7 mediates cell invasion and migration in extrahepatic cholangiocarcinoma by inducing epithelial-mesenchymal transition. Cancers (Basel) 15, 61878. https:\/\/doi.org\/10.3390\/cancers15061878 (2023).","journal-title":"Cancers (Basel)"},{"key":"91968_CR61","doi-asserted-by":"publisher","unstructured":"Roy, S., Glaser, S. & Chakraborty, S. Inflammation and progression of cholangiocarcinoma: role of angiogenic and lymphangiogenic mechanisms. Front. Med. (Lausanne) 6, 293. https:\/\/doi.org\/10.3389\/fmed.2019.00293","DOI":"10.3389\/fmed.2019.00293"},{"key":"91968_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1158\/0008-5472.CAN-03-2770","volume":"64","author":"M Taniai","year":"2004","unstructured":"Taniai, M. et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64, 10 (2004).","journal-title":"Cancer Res."},{"issue":"1","key":"91968_CR63","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-020-06804-6","volume":"20","author":"B Ma","year":"2020","unstructured":"Ma, B. et al. Distinct clinical and prognostic implication of IDH1\/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer 20(1), 318. https:\/\/doi.org\/10.1186\/s12885-020-06804-6 (2020).","journal-title":"BMC Cancer"},{"key":"91968_CR64","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2016.08.003","volume":"101","author":"AK Mehta","year":"2018","unstructured":"Mehta, A. K., Gracias, D. T. & Croft, M. TNF activity and T cells. Cytokine 101, 14\u201318. https:\/\/doi.org\/10.1016\/j.cyto.2016.08.003 (2018).","journal-title":"Cytokine"},{"issue":"1","key":"91968_CR65","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","volume":"7","author":"GH Ran","year":"2022","unstructured":"Ran., G. H. et al. Natural killer cell homing and trafficking in tissues and tumors: From biology to application. Signal. Transduct. Target. Ther. 7(1), 205. https:\/\/doi.org\/10.1038\/s41392-022-01058-z (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"91968_CR66","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2147\/OTT.S288422","volume":"14","author":"J Wang","year":"2021","unstructured":"Wang, J., Jiang, Y. H., Yang, P. Y., Liu, F. & Increased Collagen Type, V. \u03b12 (COL5A2) in colorectal Cancer is associated with poor prognosis and tumor progression. Onco Targets Ther. 14, 2991\u20133002. https:\/\/doi.org\/10.2147\/OTT.S288422 (2021).","journal-title":"Onco Targets Ther."},{"issue":"21","key":"91968_CR67","doi-asserted-by":"publisher","first-page":"21518","DOI":"10.18632\/aging.103936","volume":"12","author":"Q Liu","year":"2020","unstructured":"Liu, Q. et al. Oncostatin M expression and TP53 mutation status regulate tumor-infiltration of immune cells and survival outcomes in cholangiocarcinoma. Aging (Albany NY) 12(21), 21518\u201321543. https:\/\/doi.org\/10.18632\/aging.103936 (2020).","journal-title":"Aging (Albany NY)"},{"key":"91968_CR68","doi-asserted-by":"publisher","first-page":"114697","DOI":"10.1016\/j.biopha.2023.114697","volume":"162","author":"W Chen","year":"2023","unstructured":"Chen, W. et al. Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology. Biomed. Pharmacother. 162, 114697. https:\/\/doi.org\/10.1016\/j.biopha.2023.114697 (2023).","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"91968_CR69","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3892\/or.2018.6710","volume":"40","author":"P Lin","year":"2018","unstructured":"Lin, P. et al. Survival analysis of genome-wide profiles coupled with connectivity map database mining to identify potential therapeutic targets for cholangiocarcinoma. Oncol. Rep. 40(6), 3189\u20133198. https:\/\/doi.org\/10.3892\/or.2018.6710 (2018).","journal-title":"Oncol. Rep."},{"key":"91968_CR70","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4161\/cc.4.7.1837","volume":"4","author":"K Abell","year":"2005","unstructured":"Abell, K. & Watson, C. J. The Jak\/Stat pathway: A novel way to regulate PI3K activity. Cell. Cycle 4, 897\u2013900. https:\/\/doi.org\/10.4161\/cc.4.7.1837 (2005).","journal-title":"Cell. Cycle"},{"issue":"1","key":"91968_CR71","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3892\/ol.2018.9569","volume":"17","author":"S Tang","year":"2019","unstructured":"Tang, S. et al. Association analyses of the JAK\/STAT signaling pathway with the progression and prognosis of colon cancer. Oncol. Lett. 17(1), 159\u2013164. https:\/\/doi.org\/10.3892\/ol.2018.9569 (2019).","journal-title":"Oncol. Lett."},{"issue":"23","key":"91968_CR72","doi-asserted-by":"publisher","first-page":"11124","DOI":"10.18632\/aging.102514","volume":"11","author":"B Chen","year":"2019","unstructured":"Chen, B. et al. JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer. Aging (Albany NY). 11(23), 11124\u201311135. https:\/\/doi.org\/10.18632\/aging.102514 (2019).","journal-title":"Aging (Albany NY)"},{"key":"91968_CR73","doi-asserted-by":"publisher","first-page":"111563","DOI":"10.1016\/j.intimp.2024.111563","volume":"128","author":"Y Pei","year":"2024","unstructured":"Pei, Y., Cui, X. & Wang, Y. Regulation of IL-10 expression and function by JAK-STAT in CD8\u2009+\u2009T cells. Int. Immunopharmacol. 128, 111563. https:\/\/doi.org\/10.1016\/j.intimp.2024.111563 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"91968_CR74","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1186\/s12859-021-04379-y","volume":"22","author":"K Shen","year":"2021","unstructured":"Shen, K. et al. The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC. BMC Bioinform. 22, 1471. https:\/\/doi.org\/10.1186\/s12859-021-04379-y (2021).","journal-title":"BMC Bioinform."},{"key":"91968_CR75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.parint.2016.04.008","volume":"66","author":"M Suksawat","year":"2017","unstructured":"Suksawat, M. et al. Upregulation of endothelial nitric oxide synthase (eNOS) and its upstream regulators in Opisthorchis viverrini associated cholangiocarcinoma and its clinical significance. Parasitol. Int. 66, 4:486\u2013493. https:\/\/doi.org\/10.1016\/j.parint.2016.04.008 (2017).","journal-title":"Parasitol. Int."},{"issue":"2","key":"91968_CR76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/sjmms.sjmms_300_19","volume":"8","author":"AI Alwithenani","year":"2020","unstructured":"Alwithenani, A. I. & Althubiti, M. A. Systematic analysis of spleen tyrosine kinase expression and its clinical outcomes in various cancers. Saudi J. Med. Med. Sci. 8(2), 95\u2013104. https:\/\/doi.org\/10.4103\/sjmms.sjmms_300_19 (2020).","journal-title":"Saudi J. Med. Med. Sci."},{"key":"91968_CR77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/eji.201445226","volume":"45","author":"G Guittard","year":"2015","unstructured":"Guittard, G. et al. Absence of both Sos-1 and Sos-2 in peripheral CD4(+) T cells leads to PI3K pathway activation and defects in migration. Eur. J. Immunol. 45, 8. https:\/\/doi.org\/10.1002\/eji.201445226 (2015).","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"91968_CR78","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/mc.23543","volume":"62","author":"D Alem","year":"2023","unstructured":"Alem, D. et al. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer. Mol. Carcinog. 62(7), 1025\u20131037. https:\/\/doi.org\/10.1002\/mc.23543 (2023).","journal-title":"Mol. Carcinog."},{"key":"91968_CR79","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbrc.2022.11.015","volume":"637","author":"Y Li","year":"2022","unstructured":"Li, Y., Yin, Y., He, Y., He, K. & Li, J. SOS1 regulates HCC cell epithelial-mesenchymal transition via the PI3K\/AKT\/mTOR pathway. Biochem. Biophys. Res. Commun. 637, 161\u2013169. https:\/\/doi.org\/10.1016\/j.bbrc.2022.11.015 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"91968_CR80","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.21037\/tlcr-19-633","volume":"9","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. High integrin \u03913 expression is associated with poor prognosis in patients with non-small cell lung cancer. Transl Lung Cancer Res. 9(4), 1361\u20131378. https:\/\/doi.org\/10.21037\/tlcr-19-633 (2020).","journal-title":"Transl Lung Cancer Res."},{"key":"91968_CR81","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3389\/fgene.2020.00705","volume":"11","author":"A Wu","year":"2020","unstructured":"Wu, A. et al. Integrated analysis of prognostic and immune associated integrin family in ovarian cancer. Front. Genet. 11, 705. https:\/\/doi.org\/10.3389\/fgene.2020.00705 (2020).","journal-title":"Front. Genet."},{"key":"91968_CR82","doi-asserted-by":"publisher","first-page":"850732","DOI":"10.3389\/fonc.2022.850732","volume":"12","author":"Q Zheng","year":"2022","unstructured":"Zheng, Q., Zhang, B., Li, C. & Zhang, X. Overcome drug resistance in cholangiocarcinoma: New insight into mechanisms and refining the preclinical experiment models. Front. Oncol. 12, 850732. https:\/\/doi.org\/10.3389\/fonc.2022.850732 (2022).","journal-title":"Front. Oncol."},{"issue":"24","key":"91968_CR83","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1158\/1078-0432.CCR-22-1244","volume":"28","author":"V Sridharan","year":"2022","unstructured":"Sridharan, V. et al. FGFR mRNA expression in cholangiocarcinoma and its correlation with FGFR2 fusion status and immune signatures. Clin. Cancer Res. 28(24), 5431\u20135439. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1244 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"91968_CR84","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","volume":"19","author":"MA Krook","year":"2020","unstructured":"Krook, M. A. et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol. Cancer Ther. 19(3), 847\u2013857. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0631 (2020).","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"91968_CR85","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","volume":"188","author":"L Zamai","year":"1998","unstructured":"Zamai, L. et al. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188(12), 2375\u20132380. https:\/\/doi.org\/10.1084\/jem.188.12.2375 (1998).","journal-title":"J. Exp. Med."},{"issue":"6","key":"91968_CR86","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/ni1200","volume":"6","author":"A Matsuzawa","year":"2005","unstructured":"Matsuzawa, A. et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat. Immunol. 6(6), 587\u2013592. https:\/\/doi.org\/10.1038\/ni1200 (2005).","journal-title":"Nat. Immunol."},{"key":"91968_CR87","doi-asserted-by":"publisher","first-page":"658636","DOI":"10.3389\/fonc.2021.658636","volume":"11","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard, S. et al. 5-Fluorouracil: A narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent. Front. Oncol. 11, 658636 (2021).","journal-title":"Front. Oncol."},{"issue":"8","key":"91968_CR88","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/annonc\/mdf201","volume":"13","author":"J Ta\u00efeb","year":"2002","unstructured":"Ta\u00efeb, J. et al. Optimization of 5-fluorouracil (5-FU)\/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann. Oncol. 13(8), 1192\u20131196 (2002).","journal-title":"Ann. Oncol."},{"issue":"1","key":"91968_CR89","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12885-017-3967-0","volume":"18","author":"AR Siebenh\u00fcner","year":"2018","unstructured":"Siebenh\u00fcner, A. R. et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer18(1), 72 (2018).","journal-title":"BMC Cancer"},{"key":"91968_CR90","doi-asserted-by":"publisher","first-page":"909","DOI":"10.31557\/APJCP.2021.22.3.909","volume":"22","author":"K Kotawong","year":"2021","unstructured":"Kotawong, K., Chajaroenkul, W., Roytrakul, S., Phaonakrop, N. & Na-Bangchang, K. The proteomics and metabolomics analysis for screening the molecular targets of action of beta-eudesmol in cholangiocarcinoma. Asian Pac. J. Cancer Prev. 22, 3:909\u2013918. https:\/\/doi.org\/10.31557\/APJCP.2021.22.3.909 (2021).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"11","key":"91968_CR91","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/1440-1681.12818","volume":"44","author":"VB Mathema","year":"2017","unstructured":"Mathema, V. B., Chaijaroenkul, W., Karbwang, J. & Na-Bangchang, K. Growth inhibitory effect of \u03b2-eudesmol on cholangiocarcinoma cells and its potential suppressive effect on heme oxygenase-1 production, STAT1\/3 activation, and NF-\u03baB downregulation. Clin. Exp. Pharmacol. Physiol. 44(11), 1145\u20131154. https:\/\/doi.org\/10.1111\/1440-1681.12818 (2017).","journal-title":"Clin. Exp. Pharmacol. Physiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91968-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91968-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91968-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T16:02:57Z","timestamp":1746892977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91968-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91968"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91968-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project has approval from the Human Research Ethics Committee of Sakol Nakorn hospital (No. 049\/2563). All participants signed written informed consent forms prior to enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"16279"}}